The Impact of Different Hepatitis B Virus Serological Statuses on the Safety of Different Chemotherapy Regimens in Female Breast Cancer Patients: A Within-Subject Longitudinal Study.
Simple Summary: Breast cancer patients who are currently or were previously infected with the hepatitis B virus (HBV) face increased risks of liver injury when undergoing chemotherapy. This study examined how different HBV infection statuses affect liver safety during chemotherapy in a large group o...
| Publicado en: | Cancers Vol. 17; no. 21; pp. 3574 - 3589 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
MDPI
Nov2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189611826&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 189611826 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Nov2025 vid: 17 iid: 21 pid: 97109 pub: MDPI artinfo: ui: 189611826 189611826 189611826 10.3390/cancers17213574 189611826 ppf: 3574 ppct: 15 formats: tig: atl: The Impact of Different Hepatitis B Virus Serological Statuses on the Safety of Different Chemotherapy Regimens in Female Breast Cancer Patients: A Within-Subject Longitudinal Study. aug: au: Li, Zhao-Xing Liu, Dong-Li Hu, Lei Peng, Bai-Qing Qu, Xiu-Quan Mu, Li-Yuan Cheng, Xiao-Chun Qiu, Pu Huang, Yu-Xuan Li, Xi-Rui Kong, Ling-Quan affil: Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China sug: subj: Breast Neoplasms Drug Therapy Breast Neoplasms Complications Hepatitis Viruses Hepatitis B Complications Hepatitis B Epidemiology Chemotherapy, Adjuvant Adverse Effects Chemotherapy, Adjuvant Methods Paclitaxel Therapeutic Use Paclitaxel Adverse Effects Patient Safety Treatment Outcomes Human Female Adult Middle Age Retrospective Design Record Review Hepatotoxicity Etiology Antiviral Agents Therapeutic Use Risk Assessment Prospective Studies Linear Regression Descriptive Statistics Data Analysis Software Chi Square Test Fisher's Exact Test Post Hoc Analysis Adult: 19-44 years Middle Aged: 45-64 years Female ab: Simple Summary: Breast cancer patients who are currently or were previously infected with the hepatitis B virus (HBV) face increased risks of liver injury when undergoing chemotherapy. This study examined how different HBV infection statuses affect liver safety during chemotherapy in a large group of over 4500 patients. We found that patients with active HBV infection had the highest risk of liver injury and treatment interruptions, with the risk peaking during specific chemotherapy cycles. Even patients with past infection showed a higher need for treatment changes. These findings highlight the importance of tailored monitoring and preventive antiviral therapy for HBV-affected breast cancer patients to complete chemotherapy safely and effectively. Background: Breast cancer patients with hepatitis B virus (HBV) infection or past HBV infection face heightened risks of chemotherapy-induced hepatotoxicity and HBV reactivation (HBVr). This study aims to evaluate the impact of different HBV serological statuses on the safety of chemotherapy regimens based on paclitaxel throughout the treatment cycle. Methods: This retrospective cohort study analyzed 4562 female breast cancer patients, categorized into three groups: 366 with HBV infection (HBsAg+), 2529 with past HBV infection (HBsAg−/HBcAb+), and 1667 without HBV infection (control group). The Primary events included liver injury, HBVr, treatment interruption, and laboratory indicator evaluation. Demographic characteristics and periodic laboratory parameters were recorded for within-subject longitudinal analysis. Results: Before chemotherapy, the incidence of liver injury was highest in the HBV-infected group (18.2%), intermediate in the past-infection group (13.2%), and lowest in the control group (12.0%). Throughout chemotherapy, the cumulative incidence of liver injury remained highest in the HBV-infected group (83.2%), compared to the past-infection (71.2%) and control (70.9%) groups. Chemotherapy interruption rates followed a similar gradient: 12.4% in the HBV-infected group, 6.9% in the past-infection group, and 5.5% in the control group. HBV-infected patients had a significantly higher risk of hepatotoxicity than controls during cycle 4 (relative risk 1.56, 95% CI 1.06 to 2.29) and cycle 5 (1.28, 1.09 to 1.75). HBVr occurred in 13 patients with HBV-infected. Conclusions: HBV serological status significantly impacts chemotherapy safety and treatment interruption. Prophylactic antiviral therapy and intensified monitoring during high-risk cycles (cycle 4 and cycle 5) are critical. These findings underscore the necessity of stratified management for HBV-affected breast cancer patients during chemotherapy. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|